For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
143 [iU] per kg of body weight
71.5 [iU] per kg of body weight 2 time(s) per day every day
A daily dose of 143 IU anti-Xa/kg body weight divided in two subcutaneous injections is recommended for the initial treatment of deep vein thrombosis). The maximum daily dose is 10,307 IU. Oral anticoagulation can be started at the same time with the goal of achieving a PK-INR (International Normalised Ratio) in the therapeutic target range of 2.0–3.0. Clivarin treatment should be given for at least 5-7 days.
In clinical studies the following dose scheme has proven to be effective:
| Bodyweight | Reviparin dose | Volume |
|---|---|---|
| 35-45 kg | 2,863 IU anti-Xa twice daily | 0.50 ml |
| 46-60 kg | 3,436 IU anti-Xa twice daily | 0.60 ml |
| >60 kg | 5,153 IU anti-Xa twice daily | 0.90 ml |
For patients over 60 kg experience is available with the administration of 10,307 IU once daily.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.